Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Slides:

Advertisements

Similar presentations

Volume 50, Issue 1, Pages (July 2006)

Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Volume 58, Issue 4, Pages (October 2010)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 53, Issue 4, Pages (April 2008)

Volume 74, Issue 2, Pages (August 2018)

European Urology Oncology

Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S

Volume 61, Issue 2, Pages (February 2012)

Volume 52, Issue 4, Pages (October 2007)

Volume 65, Issue 6, Pages (June 2014)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

Volume 56, Issue 2, Pages (August 2009)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 59, Issue 4, Pages (April 2011)

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 66, Issue 2, Pages (August 2014)

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 74, Issue 2, Pages (August 2018)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

European Urology Oncology

European Urology Oncology

European Urology Oncology

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Volume 59, Issue 4, Pages (April 2011)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

Volume 74, Issue 6, Pages (December 2018)

The Cost to Medicare of Bladder Cancer Care

European Urology Oncology

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Volume 52, Issue 6, Pages (December 2007)

European Urology Oncology

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Pulmonary Resection for Metastases from Colorectal Cancer

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

European Urology Oncology

Volume 69, Issue 4, Pages (April 2016)

European Urology Oncology

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik, Harm H.E van Melick, Lea M. Dijksman, Douwe H. Biesma, J. Alfred Witjes, Jean-Paul A. van Basten European Urology Oncology Volume 1, Issue 3, Pages 231-237 (August 2018) DOI: 10.1016/j.euo.2018.03.015 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Percentage of patients not meeting the individual and overall PRIAS selection criteria (n=1000). PSA=prostate-specific antigen; PSAD=PSA density; PRIAS=Prostate Cancer Research International Active Surveillance. European Urology Oncology 2018 1, 231-237DOI: (10.1016/j.euo.2018.03.015) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier curves of time to tumour progression during active surveillance (AS). Comparison of (A) PRIAS-eligible versus PRIAS-ineligible patients and (B) prostate-specific antigen density (PSAD) <0.2 versus ≥2 ng/ml/ml. European Urology Oncology 2018 1, 231-237DOI: (10.1016/j.euo.2018.03.015) Copyright © 2018 European Association of Urology Terms and Conditions